Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases

<div>Kaplan–Meier analysis of overall survival depending on proliferation indices of primary tumors, Ki67 &lt;2% (<i>n</i> = 28; blue), Ki67 3–5% (<i>n</i> = 16; green), Ki67 6–20% (<i>n</i> = 24; yellow), Ki67 21–49% (<i>n</i> = 10; pink), and Ki67 &gt;50% (<i>n</i> = 14; red).</div>

International Journal of Endocrinology

fig3

Figure 3

Figure 3: Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases 